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An overview of surveillance methods and systems for Salmonella infections is available at  
http://www.cdc.gov/nationalsurveillance/PDFs/NationalSalmSurveillOverview_508.pdf (1).
Human Surveillance Data: Laboratory-based Enteric Disease Surveillance (LEDS)
The Laboratory-based Enteric Disease Surveillance (LEDS) system collects reports of isolates from laboratory-
confirmed human Salmonella infections from state public health laboratories.  Reporting to LEDS is voluntary, 
and the number of states submitting reports varies somewhat from year to year although almost all states report 
every year. Serotypes are summarized in this annual report as reported by state laboratories; they are usually not 
confirmed by CDC.  Occasionally, more than one isolate is reported from a single episode of infection in a person; 
this report includes only one isolate of a given Salmonella serotype per person within a 30-day period. 
In this report, we summarize the number of infections reported and also report incidence rates (cases per 100,000 
population), which are calculated as the number of Salmonella infections in humans reported for a given year 
divided by the state population for that year. 
Data were received from all 51 reporting jurisdictions (50 states plus the District of Columbia) in 2010.  For maps 
(Figures 2a to 2h), data was excluded from states where
 • the number of laboratory-confirmed human Salmonella isolates reported to LEDS was less than 20% of the 
number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS)
 » 8 reporting jurisdictions were excluded: Florida, Illinois, Kansas, Louisiana, Nevada, South Carolina, 
Tennessee, Vermont
 • the number of fully serotyped laboratory-confirmed human Salmonella isolates reported to LEDS was less than 
20% of Salmonella isolates reported to LEDS:
 » 7 reporting jurisdictions were excluded: Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming
Data in this report current as of 1/14/2013.
Colorized scanning electron micrograph (SEM) of clustered Gram-negative 
Salmonella typhimurium bacteria.
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Table 1. Laboratory-confirmed human Salmonella infections reported to CDC, with the 20 most frequently 
reported serotypes listed individually, United States, 2010
Rank Serotype Number Reported Percent
1 Enteritidis 8915 19.2
2 Typhimurium (including Typhimurium var. 5-) 6129 13.2
3 Newport 5067 10.9
4 Javiana 3020 6.5
5 I 4,[5],12:i:- 1192 2.6
6 Heidelberg 1099 2.4
7 Montevideo 1067 2.3
8 Saintpaul 890 1.9
9 Muenchen 833 1.8
10 Infantis 813 1.8
11 Branderup 731 1.6
12 Oranienburg 662 1.4
13 Agona 509 1.1
14 Thompson 482 1.0
15 Typhi 479 1.0
16 Mississippi 475 1.0
17 Paratyphi B var. L(+) tartrate+ 451 1.0
18 Schwarzengrund 395 0.9
19 Bareilly 339 0.7
20 Poona 271 0.6
Sub Total 33819 73.0
All Other Serotyped 6854 14.8
Unknown 4095 8.8
Partially serotyped 1338 2.9
Rough, mucoid, and/or nonmotile isolates 233 0.5
Sub Total 12520 27.0
Total 46339 100
All serotyped isolates are listed in Table 3
State public health laboratories reported 46,339 laboratory-confirmed Salmonella infections to CDC 
through LEDS
 • The top 4 serotypes were Enteritidis (19%), Typhimurium (including Typhimurium var. 5- ) (13%), 
Newport (11%), and Javiana (7%).
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Table 2. Laboratory-confirmed human Salmonella infections reported to CDC, percent change among the 20 most 
frequently reported serotypes, comparing 2000, 2005, and 2010 
Rank Number Reported Percent Change
2000 2005 2010 Serotype 2000 2005 2010
2000 
vs 
2005
2005 
vs 
2010
2000 
vs 
2010
2 2 1 Enteritidis 6487 6732 8915 4 32 37
1 1 2 Typhimurium* 7428 6987 6129 -6 -12 -17
3 3 3 Newport 3074 3300 5067 7 54 65
5 5 4 Javiana 1204 1324 3020 10 128 151
21 6 5 I 4,[5],12:i:- 233 884 1192 279 35 412
4 4 6 Heidelberg 1772 1905 1099 8 -42 -38
6 7 7 Montevideo 841 809 1067 -4 32 27
11 9 8 Saintpaul 548 685 890 25 30 62
7 8 9 Muenchen 642 733 833 14 14 30
8 13 10 Infantis 613 506 813 -17 61 33
12 10 11 Braenderup 531 603 731 14 21 38
10 11 12 Oranienburg 563 590 662 5 12 18
14 16 13 Agona 406 369 509 -9 38 25
9 15 14 Thompson 609 428 482 -30 13 -21
15 17 15 Typhi 399 350 479 -12 37 20
19 12 16 Mississippi 286 566 475 98 -16 66
13 14 17 Paratyphi B var. L(+) tartrate+ 468 460 451 -2 -2 -4
33 29 18 Schwarzengrund 113 139 395 23 184 250
23 22 19 Bareilly 182 201 339 10 69 86
17 24 20 Poona 337 196 271 -42 38 -20
Note:  * Typhimurium includes var. 5- (formerly var. Copenhagen)
Although reports of serotype I 4,[5],12:i:- increased 412% in 2010 from 2000, this reflects, for the most part, a 
change in reporting practice (1).  
In 2010, serotype Schwarzengrund had the largest increase (250%) compared with 2000 of any of the top 20 
serotypes for which surveillance has been stable; most of this increase occurred after 2005.
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Figure 1. Incidence rate of laboratory-confirmed human Salmonella infection reported to CDC (all serotypes and 
serotypes with more than 1000 infections reported to CDC in 2010), United States, 1970–2010
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The top panel of this graph shows the incidence rate of infection with Salmonella (all serotypes) and with 
serotypes Typhimurium (including serotype Typhimurium var. 5-) and Enteritidis from 1970 to 2010
 • Since 1970, the incidence rate of infection with all Salmonella has been driven largely by the incidence rate of 
infection with serotypes Typhimurium (including serotype Typhimurium var. 5-) and Enteritidis
 • The spike in incidence rate seen in 1985 reflects an outbreak of Salmonella serotype Typhimurium infections 
associated with pasteurized milk (2)
The bottom panel of this graph shows the incidence rate of infection with all serotypes of Salmonella with more 
than 1000 infections reported to CDC in 2010: this includes serotypes Newport, Javiana, I, 4,[5],12:i:-, Heidelberg, 
Montevideo, and infections with an unknown, rough, or partial serotype 
 • The incidence rate of infection with serotype Heidelberg has been decreasing steadily following a peak in 1987
 • Since the late 1990s, the incidence rates of infection with serotypes Javiana, Newport, and I,4,[5],12:i:- have 
been steadily increasing 
 • Since 2000, the incidence of infection with isolates with an unknown, rough, or partial serotype have been 
increasing
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Figure 2a. Incidence rate of laboratory-confirmed human Salmonella infection reported to CDC (all serotypes), 
by reporting jurisdiction, United States, 2010*
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* Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  
The reporting jurisdictions with the highest reported incidence rates (cases per 100,000 population) of Salmonella 
infection were Mississippi (32.9), Alabama (28.8), and North Carolina (28.6). 
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Figure 2b. Incidence rate of laboratory-confirmed human Salmonella serotype Enteritidis infection reported to CDC, 
by reporting jurisdiction, United States, 2010*
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*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming). 
The reporting jurisdictions with the highest reported incidence rates of serotype Enteritidis infection (cases per 
100,000 population) were Maryland (6.5), District of Columbia (5.8), and Rhode Island (5.2).  
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Figure 2c. Incidence rate of laboratory-confirmed human Salmonella serotype Typhimurium (including 
Typhimurium var. 5-) infection reported to CDC, by reporting jurisdiction, United States, 2010*
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Legend
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*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  
The reporting jurisdictions with the highest reported incidence rates of serotype Typhimurium (including 
Typhimurium var. 5-) infection (cases per 100,000 population) were South Dakota (7.1), Mississippi (6.9),  and 
Alabama (5.8). 
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Figure 2d. Incidence rate of laboratory-confirmed human Salmonella serotype Newport infection reported to CDC, 
by reporting jurisdiction, United States, 2010*
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*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  
The reporting jurisdictions with the highest reported incidence rates of serotype Newport infection (cases per 
100,000 population) were Arkansas (8.0), North Carolina (6.5), and Mississippi (6.2). 
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Figure 2e. Incidence rate of laboratory-confirmed human Salmonella serotype Javiana infection reported to CDC, 
by reporting jurisdiction, United States, 2010* 
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*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  
The reporting jurisdictions with the highest reported incidence rates of serotype Javiana infection (cases per 
100,000 population) were Mississippi (6.0),Georgia (5.6), and Alabama (4.9). 
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Figure 2f. Incidence rate of laboratory-confirmed human Salmonella serotype I,4,[5],12:i:- infection reported to CDC, 
by reporting jurisdiction, United States, 2010* 
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*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  Reporting 
jurisdictions shaded with grey lines are those that were not excluded from mapping but that reported no infections with this serotype. 
The  reporting jurisdictions with the highest reported incidence rates of serotype I,4,[5],12:i:- infection (cases per 
100,000 population) were Iowa (1.4), Alabama (1.4) and Rhode Island (0.95).   
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Figure 2g. Incidence rate of laboratory-confirmed human Salmonella serotype Heidelberg infection reported to 
CDC, by reporting jurisdiction, United States, 2010* 
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*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  
The reporting jurisdictions with the highest reported incidence rates of serotype Heidelberg infection (cases per 
100,000 population) were Alaska (1.4), Arizona (1.0), and Idaho (0.95).
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Figure 2h. Incidence rate of laboratory-confirmed human Salmonella serotype Montevideo infection reported to 
CDC, by reporting jurisdiction, United States, 2010* 
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*Unshaded reporting jurisdictions are those excluded from mapping because  the number of laboratory-confirmed human Salmonella isolates reported 
to LEDS was less than 20% of the number of salmonellosis cases reported to the National Notifiable Diseases Surveillance System (NNDSS) (Florida, Illinois, 
Kansas, Louisiana, Nevada, South Carolina, Tennessee, Vermont) or because the number of fully serotyped laboratory-confirmed human Salmonella isolates 
reported to LEDS was  less than 20% of Salmonella isolates reported to LEDS (Kentucky, Maine, Montana, Nebraska, Texas, Utah, Wyoming).  Reporting 
jurisdictions shaded with grey lines are those that were not excluded from mapping but that reported no infections with this serotype. 
The reporting jurisdictions with the highest reported incidence rates of serotype Montevideo infection (cases per 
100,000 population) were Mississippi (1.2), Alabama (1.1), and South Dakota (0.98). 
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Figure 3. Incidence rate of laboratory-confirmed human Salmonella infection reported to CDC, by age group 
and sex, United States, 2010 (n=46,339)
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During 2010, the highest incidence rate of Salmonella infections was in children under 5 years old.  From ages 0 
to 19, males had a higher incidence rate of Salmonella  infections than females; from age 20 to 80+, females had a 
higher incidence rate of Salmonella infections than males.
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Figure 4. Number of laboratory-confirmed human Salmonella infections reported to CDC, by month of specimen 
collection, United States, 2010 and average number during 2000 to 2009
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Compared with the previous 10 years (2000-2009), more Salmonella infections were reported in 2010.  During  
2010, reports of Salmonella infections showed seasonality similar to the average reported during 2000 to 2009, 
with a summer peak and the largest number of infections reported in August.
Page 15 of 19June 2013
Human Surveillance Data: National Notifiable Diseases  
Surveillance System (NNDSS)
The National Notifiable Disease Surveillance System (NNDSS) collects and compiles reports of nationally notifiable 
infectious diseases, including salmonellosis.  This system includes reports of laboratory-confirmed cases and 
probable cases (clinically compatible cases with an epidemiological link to a confirmed case). 
The 2010 NNDSS report is available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5953a1.htm. 
 • A total of 47,150 confirmed cases of salmonellosis were reported to NNDSS during 2010; serotype information 
was not available in this system for 2010 (3).
Human Antimicrobial Resistance Data: National Antimicrobial Resistance 
Monitoring System (NARMS)
The National Antimicrobial Resistance Monitoring System (NARMS) monitors antimicrobial resistance among 
enteric bacteria (including Salmonella) isolated from humans.  The 2010 NARMS report on human infections is 
available at http://www.cdc.gov/narms/pdf/2010-annual-report-narms.pdf  (4) and is excerpted below.
In the United States, fluoroquinolones (e.g., ciprofloxacin) and third-generation cephalosporins (e.g., ceftriaxone) 
are commonly used to treat severe Salmonella infections, including Salmonella serotype Typhi, the organism 
that causes typhoid fever.  In Enterobacteriaceae, resistance to nalidixic acid, an elementary quinolone, correlates 
with decreased susceptibility to ciprofloxacin (MIC ≥0.12 μg/mL) and possible fluoroquinolone treatment failure. 
Ceftiofur is a third-generation cephalosporin used in food animals in the United States; resistance to ceftiofur 
among Enterobacteriaceae correlates with resistance to ceftriaxone (MIC ≥4 μg/mL).
 • 2.0% of nontyphoidal (nontyphoidal Salmonella refers to all Salmonella serotypes other than Typhi, Paratyphi A, 
Paratyphi B1, and Paratyphi C) Salmonella infections were resistant to nalidixic acid, including 
 » 5.2%  of serotype Enteritidis infections 
 » The most common serotype among the nalidixic acid-resistant infections was Enteritidis (55.1%)
 • 2.8% of nontyphoidal Salmonella infections were resistant to ceftriaxone, including 
 » 24.2% of serotype Heidelberg infections , 
 » 7.2% of serotype Newport infections, and
 » 4.9% of serotype Typhimurium infections.
 » The most common serotype among the ceftriaxone-resistant infections was Newport (31.4%)
 • 69.1% of serotype Typhi infections were resistant to nalidixic acid and 2.7% to ciprofloxacin
1  Two distinct pathotypes of Salmonella serotype Paratyphi B are recognized; one pathotype is associated with paratyphoid fever and the other is associated 
with uncomplicated gastroenteritis.  The two pathotypes are known to have distinct virulence characteristics, but are currently differentiated based on the 
ability to ferment tartrate.  The paratyphoidal pathotype is unable to ferment tartrate and is designated serotype Paratyphi B; the gastrointestinal pathotype 
ferments tartrate and is designated serotype Paratyphi B var. L(+) tartrate+. 
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Multidrug resistance is described in NARMS as resistance to three or more antimicrobial classes and also 
by specific co-resistant phenotypes. Classes of antimicrobial agents defined by the Clinical and Laboratory 
Standards Institute (CLSI) are used by NARMS.
 • 11.3% of nontyphoidal Salmonella infections were resistant to two or more CLSI classes
 • 9.1% were resistant to three or more CLSI classes. Those resistant to three or more classes included
 » 33.9% of serotype Heidelberg infections 
 » 27.3% of serotype Typhimurium infections 
 » 22.1% of serotype I,4,[5],12:i:- infections
 • 44.4% of nontyphoidal Salmonella infections that were resistant to three or more classes were serotype 
Typhimurium. 
Human Outbreak Data: Foodborne Disease Outbreak Surveillance System 
(FDOSS) and Waterborne Disease Outbreak Surveillance System (WBDOSS)
The Foodborne Disease Outbreak Surveillance System (FDOSS) collects reports of foodborne disease outbreaks 
from local, state, and territorial public health agencies.  The 2009 to 2010 summary of foodborne disease 
outbreaks is available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a1.htm?s_cid=mm6203a1_w 
 • In 2010, 121 confirmed, single-etiology Salmonella outbreaks with 2,274 illnesses were reported (4).
 » The most common serotype causing confirmed, single-etiology Salmonella outbreaks was Enteritidis (76 
outbreaks, 63%) (5).
 • In 2010, 13 multistate outbreaks caused by Salmonella were reported. 
The Waterborne Disease and Outbreak Surveillance System (WBDOSS) collects reports of waterborne disease 
outbreaks associated with drinking water and recreational water from local, state, tribal, and territorial public 
health agencies.  The report for 2010 was not available when this was written.  Reports are available at  
http://www.cdc.gov/healthywater/statistics/wbdoss/surveillance.html.
Non-human Surveillance Data: National Veterinary Services Labortories (NVSL)
The data in tables 3, 4, and 5 come from the National Veterinary Services Laboratories (NVSL) of the United States 
Department of Agriculture’s Animal and Plant Health Inspection Service (USDA-APHIS).  Isolates from Salmonella 
infections are submitted to NVSL by veterinary diagnostic laboratories throughout the United States for 
serotyping.  Clinical animal infections (referred to as “clinical/non-human”) are Salmonella infections in animals 
with clinical signs of illness; “non-clinical/non-human” infections are Salmonella infections identified through 
herd and flock monitoring and surveillance, feed sample testing, environmental testing, and USDA-FSIS food 
testing programs.  
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Table 3a. Laboratory-confirmed Salmonella isolates from clinical non-human sources submitted to the National 
Veterinary Services Laboratories (NVSL) for typing, with the 20 most frequently reported serotypes listed 
individually, 2010
Clinical Non-human 2010
Rank Serotype Reported Percent
1 Typhimurium* 953 20.1
2 Dublin 279 5.9
3 Cerro 228 4.8
4 Newport 211 4.4
5 Agona 207 4.4
6 I 4,[5],12:i:- 184 3.9
7 Derby 179 3.8
8 Heidelberg 158 3.3
9 Montevideo 155 3.3
10 Senftenberg 137 2.9
11 Anatum 135 2.8
12 Javiana 135 2.8
13 Enteritidis 134 2.8
14 Kentucky 97 2.0
15 Infantis 89 1.9
16 Mbandaka 76 1.6
17 Worthington 64 1.3
18 Choleraesuis** 53 1.1
19 Oranienburg 51 1.1
20 Melagridis 50 1.1
Sub Total 3575 75.4
All Other Serotyped 972 20.5
Unknown 43 0.9
Rough, mucoid, and/or nonmotile isolates 154 3.2
Sub Total 1169 24.6
Total 4744 100
Note:   
  * Typhimurium includes var. 5- (formerly var. Copenhagen) 
** Choleraesuis includes var. Decatur and Kunzendorf
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Table 3b. Laboratory-confirmed Salmonella isolates from non-clinical non-human sources submitted to the 
National Veterinary Services Laboratories (NVSL) for typing, with the 20 most frequently reported 
serotypes listed individually, 2010 
Non-Clinical Non-human 2010
Rank Serotype Reported Percent
1 Enteritidis 1449 17.7
2 Kentucky 1116 13.6
3 Senftenberg 680 8.3
4 Typhimurium* 505 6.2
5 Heidelberg 323 3.9
6 Montevideo 323 3.9
7 Cerro 216 2.6
8 Mbandaka 209 2.6
9 Infantis 179 2.2
10 Newport 173 2.1
11 Anatum 161 2.0
12 Agona 129 1.6
13 Tennessee 117 1.4
14 Hadar 111 1.4
15 Dublin 95 1.2
16 Braenderup 94 1.1
17 I 4,[5],12:i:- 91 1.1
18 Muenster 86 1.1
19 Worthington 86 1.1
20 Schwarzengrund 78 1.0
Sub Total 6221 76.0
All Other Serotyped 1659 20.2
Rough, mucoid, and/or nonmotile isolates 310 3.8
Sub Total 1969 24.0
Total 8190 100
Note:   
* Typhimurium includes var. 5- (formerly var. Copenhagen)
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Table 4. Laboratory-confirmed Salmonella isolates from clinical non-human animal sources (bovine, chicken, 
porcine, and turkey) submitted to the National Veterinary Services Laboratories (NVSL) for typing, for the 
top 4 serotypes causing human illness in 2010, by source. 
Non-Human (clinical) Sources
Serotype Human Rank, 2010 Bovine (%) Chicken (%) Porcine (%) Turkey (%)
Enteritidis 1 4.5 78.4 4.5 0
Typhimurium (including 
Typhimurium var. 5-)
2 16.5 4.2 52.2 1.9
Newport 3 42.7 0 3.3 2.4
Javiana 4 1.5 0 0 0
Table 5. Laboratory-confirmed Salmonella isolates  from non-clinical non-human animal sources (bovine, chicken, 
porcine, and turkey) submitted to the National Veterinary Services Laboratories (NVSL) for typing, for the 
top 4 serotypes causing human illness in 2010, by source.
Non-Human (non-clinical) Sources
Serotype Human Rank, 2010 Bovine (%) Chicken (%) Porcine (%) Turkey (%)
Enteritidis 1 0.1 96.3 0 0.2
Typhimurium (including 
Typhimurium var. 5-)
2 10.9 44.0 8.1 4.8
Newport 3 15.0 21.4 0.6 5.2
Javiana 4 2.0 12.0 0 0
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